To ask the Secretary of State for Health and Social Care, what steps he is taking to help support access to genomically-matched targeted therapies for patients with rare cancers, where genomic testing identifies a suitable option but large-scale clinical trial evidence is unlikely to be generated.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are working to deliver the Government’s ambitions, as set out in the 10-Year Health Plan for England and the Life Sciences Sect...
Rare Cancers: Medical Treatments